Abstract
A series of 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivatives which were highly active against autoluminescent Mycobacterium tuberculosis (Mtb) and Mycobacterium marinum (Mm) in an in vitro assay were identified. SAR analysis showed that the most active compounds, which included a phenyl group bearing fluoro substituent(s) at C2, a methoxy function at C3, and a benzyl-heteroatom moiety at C6, exhibited in vitro MIC90 values generally around 0.63–1.26 μM against Mtb and Mm. However, these compounds were inactive against Mtb in vivo (mice), and investigations revealed very short metabolic half-lives (<10 min) when incubated with mouse liver microsomes. Multiple observations of side products produced from oxidative cleavage of the imidazole moiety during the chemical synthesis work suggested that this is a likely metabolic pathway leading to the lack of observed activity in vivo.
Original language | English |
---|---|
Article number | 115637 |
Number of pages | 27 |
Journal | European Journal of Medicinal Chemistry |
Volume | 259 |
Early online date | 19 Jul 2023 |
DOIs | |
Publication status | Published - 5 Nov 2023 |
Keywords
- Antimycobacterial activity
- Imidazo[1,2-b]pyridazine
- Metabolism
- Mycobacterium tuberculosis
- Pharmacokinetic
- SAR
- Synthesis